India Glycols Limited — PPTs, 11-08-2025: Investor Presentation

**Financial Highlights:**

For Q1 FY26, gross revenue climbed 9.7% YoY to ₹2,503 Cr, with net revenue up 7.4% to ₹1,040 Cr. EBITDA jumped 17.7% to ₹151 Cr, expanding margins by 128 bps to 14.5%. Profit after tax (PAT) rose 21.3% to ₹73 Cr, with PAT margins at 7.0%. Growth was driven by Bio Fuel (+45.4% revenue) and Potable Spirits (+22.4% revenue), while PS and BSPC segments saw healthy EBIT margin expansion. Joint venture profits also increased significantly.

**Strategic Initiatives & Growth Drivers:**

The company proposes a demerger into three separate entities: India Glycols Limited (Chemicals, Industrial Gases), IGL Spirits Limited (Potable Spirits, Bio-Fuel), and Ennature Bio Pharma Limited (Bio Pharma, Bio Polymers). This aims for clear business focus, value unlocking, efficient capital allocation, and independent growth. Expanded Bio Fuel capacity supports government blending targets, and new bio-based amines highlight green chemistry leadership.

**Business Developments:**

A 1:2 stock split was announced, increasing equity shares from approx. 3.1 Cr to 6.2 Cr. The Potable Spirits segment gained traction with the Amrut partnership and successful brand approvals for Zumba Lemoni and Amazing in Kerala. "Bunty Bubli" continues as a top-selling brand, solidifying market position.

**Market Position & Competitive Advantage:**

IGL positions itself as a leader in Bio-based Specialties & Performance Chemicals and holds market leadership in Country Liquor in key states. Its "Green Chemical Company" identity is underscored by manufacturing bio-ethylene glycols and other bio-based products using innovative green technologies and integrated manufacturing facilities.

**Investor Implications:**

The proposed demerger and strong Q1 performance in key segments like Bio Fuel and Potable Spirits indicate positive growth potential. The focus on green chemistry and diversified business model adds resilience. Investors should monitor performance in the Ennature Biopharma segment, which faced headwinds.